ISRG Research Update — April 22, 2026
Updated Thesis
Intuitive Surgical, Inc. is a leading healthcare company specializing in robotic-assisted surgery through its flagship da Vinci system, which has established a durable competitive moat with approximately 10,000 systems installed globally and nearly 17 million procedures performed by the end of 2024. The company benefits from a high-quality business model characterized by 85% recurring revenue, strong gross margins of 66.3%, and consistent revenue growth of 23% in the most recent quarter.
The investment grade as of this refresh is B — solid business quality. High-tier business, mid-tier valuation with 130% upside to $1039.74 fair value
Key Metrics at a Glance
- Revenue growth: +23.0% year over year
- Net margin: 28.2%
- Forward P/E: 53.8x
- Fair value upside: +130.4% to our estimate of $1040
Current price: $451.29
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Intuitive Surgical, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ISRG research →](/stocks/ISRG)